Koji Abe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Koji Abe has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
Mami Takemoto
Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan
8 shared publicationsNozomi Hishikawa
Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan
8 shared publications- Koh Tadokoro
Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
6 shared publications - Toru Yamashita
Department of Neurology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan
6 shared publications Yasuyuki Ohta
Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan
6 shared publicationsRyo Sasaki
Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan
5 shared publications
Latest Publications
- 7 March 2020
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 8 (3) , 164-166
A spontaneous recovery of anti‐galactocerebroside antibody‐associated encephalitis without evidence of Mycoplasma infection
- 7 March 2020
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 8 (3) , 164-166
A spontaneous recovery of anti‐galactocerebroside antibody‐associated encephalitis without evidence of Mycoplasma infection
- 24 August 2019
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 71 (3) , 1063-1069
Clinical Benefits of Antioxidative Supplement Twendee X for Mild Cognitive Impairment: A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Prospective Interventional Study
Oxidative stress is part of the entire pathological process that underlies the development of Alzheimer’s disease (AD), including the mild cognitive impairment (MCI) stage. Twendee X (TwX) is a supplement containing a strong antioxidative mix of eight antioxidants, which has been shown to have a clinical and therapeutic benefit in AD model mice. Here, we conducted a multicenter, randomized, double-blind, and placebo-controlled prospective interventional study to evaluate the efficacy of TwX in mitigating MCI. The primary outcomes were differences in Mini-Mental State Examination (MMSE) and Hasegawa Dementia Scale-revised (HDS-R) scores between baseline and six months for placebo and TwX groups. Seventy-eight subjects with MCI were randomized into placebo ( n = 37) and TwX ( n = 41) groups. MMSE scores at six months differed significantly between the TwX and placebo groups ( p = 0.018), and HDS-R scores for the TwX group exhibited a significant improvement at six months relative to baseline ( p = 0.025). The TwX group did not show any change in affective or activities of daily living scores at six months. The present study indicates that strong antioxidative supplement TwX is clinical beneficial for cognitive function in subjects with MCI.
- 24 August 2019
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 71 (3) , 1063-1069
Clinical Benefits of Antioxidative Supplement Twendee X for Mild Cognitive Impairment: A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Prospective Interventional Study
Oxidative stress is part of the entire pathological process that underlies the development of Alzheimer’s disease (AD), including the mild cognitive impairment (MCI) stage. Twendee X (TwX) is a supplement containing a strong antioxidative mix of eight antioxidants, which has been shown to have a clinical and therapeutic benefit in AD model mice. Here, we conducted a multicenter, randomized, double-blind, and placebo-controlled prospective interventional study to evaluate the efficacy of TwX in mitigating MCI. The primary outcomes were differences in Mini-Mental State Examination (MMSE) and Hasegawa Dementia Scale-revised (HDS-R) scores between baseline and six months for placebo and TwX groups. Seventy-eight subjects with MCI were randomized into placebo ( n = 37) and TwX ( n = 41) groups. MMSE scores at six months differed significantly between the TwX and placebo groups ( p = 0.018), and HDS-R scores for the TwX group exhibited a significant improvement at six months relative to baseline ( p = 0.025). The TwX group did not show any change in affective or activities of daily living scores at six months. The present study indicates that strong antioxidative supplement TwX is clinical beneficial for cognitive function in subjects with MCI.
- 1 October 2018
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 393, 142-144
Congenital myopathy with fiber-type disproportion accompanied by dilated cardiomyopathy in a patient with a novel p.G48A ACTA1 mutation
- 1 October 2018
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 393, 142-144
Congenital myopathy with fiber-type disproportion accompanied by dilated cardiomyopathy in a patient with a novel p.G48A ACTA1 mutation
- 21 August 2018
- Published by Wiley in Geriatrics & Gerontology International
- Vol. 18 (9) , 1383-1387
Clinical characteristics of patients with dementia in a local emergency clinic in Japan
Aim: The present study aimed to clarify the clinical characteristics of patients with dementia in an emergency clinic.Methods: We retrospectively examined patients with dementia who visited the emergency clinic at Kurashiki Heisei Hospital, Okayama, Japan. Among 16 764 patients who visited our emergency clinic in the 3 years from 2014 to 2017, we focused on 2574 (15.4%) patients with dementia.Results: The mean age of patients with dementia was 84.9 ± 0.1 years, which was much older than the age of the total emergency patients (58.1 ± 0.2 years). The hospitalization rate was 54.9% for patients with dementia, which was more than double that of patients without dementia (23.3%; P P P ≤ 0.05).Conclusions: Patients with dementia commonly attend our emergency clinic. These patients are older in age, have a higher hospitalization rate and have a longer hospitalization, especially due to stroke and falls, than patients without dementia. Geriatr Gerontol Int 2018; 18: 1383–1387.
- 21 August 2018
- Published by Wiley in Geriatrics & Gerontology International
- Vol. 18 (9) , 1383-1387
Clinical characteristics of patients with dementia in a local emergency clinic in Japan
Aim: The present study aimed to clarify the clinical characteristics of patients with dementia in an emergency clinic.Methods: We retrospectively examined patients with dementia who visited the emergency clinic at Kurashiki Heisei Hospital, Okayama, Japan. Among 16 764 patients who visited our emergency clinic in the 3 years from 2014 to 2017, we focused on 2574 (15.4%) patients with dementia.Results: The mean age of patients with dementia was 84.9 ± 0.1 years, which was much older than the age of the total emergency patients (58.1 ± 0.2 years). The hospitalization rate was 54.9% for patients with dementia, which was more than double that of patients without dementia (23.3%; P P P ≤ 0.05).Conclusions: Patients with dementia commonly attend our emergency clinic. These patients are older in age, have a higher hospitalization rate and have a longer hospitalization, especially due to stroke and falls, than patients without dementia. Geriatr Gerontol Int 2018; 18: 1383–1387.
- Open Access
- 1 August 2018
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 57 (15) , 2243-2246
A Japanese Encephalitis Patient Presenting with Parkinsonism with Corresponding Laterality of Magnetic Resonance and Dopamine Transporter Imaging Findings
Japanese encephalitis (JE) survivors often present with nigrostriatal aftereffects with parkinsonian features. A 67-year-old woman with JE showed right-dominant clinical parkinsonism and left-dominant substantia nigra lesions after magnetic resonance imaging (MRI). Dopamine transporter (DAT) imaging using 123I-labeled 2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl)-nortropane (123I-FP-CIT) revealed a corresponding left-dominant decrease. The present case is the first to reveal a clear match of laterality between clinical parkinsonism, MRI-based substantia nigra lesions, and impaired DAT in presynaptic dopaminergic neurons in JE.
- 1 August 2018
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 57 (15) , 2243-2246
Open AccessA Japanese Encephalitis Patient Presenting with Parkinsonism with Corresponding Laterality of Magnetic Resonance and Dopamine Transporter Imaging Findings
Japanese encephalitis (JE) survivors often present with nigrostriatal aftereffects with parkinsonian features. A 67-year-old woman with JE showed right-dominant clinical parkinsonism and left-dominant substantia nigra lesions after magnetic resonance imaging (MRI). Dopamine transporter (DAT) imaging using 123I-labeled 2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl)-nortropane (123I-FP-CIT) revealed a corresponding left-dominant decrease. The present case is the first to reveal a clear match of laterality between clinical parkinsonism, MRI-based substantia nigra lesions, and impaired DAT in presynaptic dopaminergic neurons in JE.
- 15 May 2018
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 388, 7-9
A mild myopathy with anti-SRP plus anti-PL-12 antibodies successfully treated by oral steroid monotherapy
- 15 May 2018
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 388, 7-9
A mild myopathy with anti-SRP plus anti-PL-12 antibodies successfully treated by oral steroid monotherapy
- 23 August 2017
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 5 (5) , 162-164
Non‐ketotic hyperosmolar coma after percutaneous endoscopic gastrostomy in an advanced stage of progressive supranuclear palsy
Patients with progressive supranuclear palsy often suffer from dysphagia, and percutaneous endoscopic gastrostomy is a treatment option for the advanced stage of this disease. The present percutaneous endoscopic gastrostomy patient had slightly impaired glucose tolerance, but the condition became considerably worse with normal nutrients due to limited activity and an infection after percutaneous endoscopic gastrostomy, resulting in a non‐ketotic hyperosmolar coma. After receiving supplementary fluid, intravenous insulin, antibiotics and endotracheal intubation, the patient recovered from the non‐ketotic hyperosmolar coma state. Percutaneous endoscopic gastrostomy placement at an advanced stage of a neurodegenerative disorder, such as progressive supranuclear palsy, should have a careful follow‐up, especially when glucose tolerance worsens.
- 23 August 2017
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 5 (5) , 162-164
Non‐ketotic hyperosmolar coma after percutaneous endoscopic gastrostomy in an advanced stage of progressive supranuclear palsy
Patients with progressive supranuclear palsy often suffer from dysphagia, and percutaneous endoscopic gastrostomy is a treatment option for the advanced stage of this disease. The present percutaneous endoscopic gastrostomy patient had slightly impaired glucose tolerance, but the condition became considerably worse with normal nutrients due to limited activity and an infection after percutaneous endoscopic gastrostomy, resulting in a non‐ketotic hyperosmolar coma. After receiving supplementary fluid, intravenous insulin, antibiotics and endotracheal intubation, the patient recovered from the non‐ketotic hyperosmolar coma state. Percutaneous endoscopic gastrostomy placement at an advanced stage of a neurodegenerative disorder, such as progressive supranuclear palsy, should have a careful follow‐up, especially when glucose tolerance worsens.
- 4 May 2017
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 5 (3) , 96-98
Familial amyotrophic lateral sclerosis of the G37V‐ superoxide dismutase 1 mutation with a slow disease progression
The majority of amyotrophic lateral sclerosis patients have the sporadic form, but 5–10% of those have familial amyotrophic lateral sclerosis. A total of 15–20% of familial amyotrophic lateral sclerosis patients have genetic mutations in the superoxide dismutase 1 gene. In 2012, Kobayashi et al. reported the first case of a familial amyotrophic lateral sclerosis patient carrying a G37V superoxide dismutase 1 mutation, who showed rapid progression and died within 1.2 years of onset from respiratory failure. In contrast, here we report the second case of familial amyotrophic lateral sclerosis carrying the G37V superoxide dismutase 1 mutation, showing a very slow progression, and his father and aunt also had longer disease durations from 4 to 6 years. Further clinical and biological studies will clarify the detailed pathological role of the G37V superoxide dismutase 1 mutation for amyotrophic lateral sclerosis.
- 4 May 2017
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 5 (3) , 96-98
Familial amyotrophic lateral sclerosis of the G37V‐ superoxide dismutase 1 mutation with a slow disease progression
The majority of amyotrophic lateral sclerosis patients have the sporadic form, but 5–10% of those have familial amyotrophic lateral sclerosis. A total of 15–20% of familial amyotrophic lateral sclerosis patients have genetic mutations in the superoxide dismutase 1 gene. In 2012, Kobayashi et al. reported the first case of a familial amyotrophic lateral sclerosis patient carrying a G37V superoxide dismutase 1 mutation, who showed rapid progression and died within 1.2 years of onset from respiratory failure. In contrast, here we report the second case of familial amyotrophic lateral sclerosis carrying the G37V superoxide dismutase 1 mutation, showing a very slow progression, and his father and aunt also had longer disease durations from 4 to 6 years. Further clinical and biological studies will clarify the detailed pathological role of the G37V superoxide dismutase 1 mutation for amyotrophic lateral sclerosis.